BioWorld-International-2010-07-07
Study Reveals a Dozen New Diabetes Genes to Explore
Intercell's Adjuvant Patch Fails to Boost Pandemic Flu Vaccine
A faulty hemagglutinin inhibition assay may be the reason underlying the failure of a Phase II clinical trial of Intercell AG's investigational Vaccine Enhancement Patch (VEP) for H5N1 influenza. (BioWorld International)

